Zealand Pharma's petrelintide hits Phase 2 weight and glycaemic goals
Zealand Pharma has reported positive topline results from ZUPREME-2, a Phase 2b trial evaluating its once-weekly amylin analogue petrelintide in 220 people living with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, with all three petrelintide dose arms delivering statistically significant reductions in body weight from baseline at 28 weeks.
Participants receiving petrelintide achieved a mean weight loss of between 7.4% and 9.2% from baseline on the efficacy estimand, compared with 2.0% for those on placebo. Glycaemic control also improved: petrelintide produced a placebo-adjusted HbA1c reduction of 0.61% to 0.88% across the dose arms, against an increase of 0.23% in the placebo group. The dual benefit in weight and glucose management will be seen as a clinically meaningful distinction in a diabetes-adjacent obesity indication.
Tolerability sets petrelintide apart
One of the more striking numbers in the release concerns tolerability. Gastrointestinal adverse events are the central limitation of GLP-1 receptor agonists, the current standard of care in obesity pharmacotherapy, and high discontinuation rates attributable to nausea remain a commercial and clinical liability for the class. In ZUPREME-2, the discontinuation rate due to gastrointestinal adverse events was 1.9% for petrelintide versus 1.7% for placebo, a difference that is clinically negligible. Most gastrointestinal events that did occur were mild and clustered during the dose-escalation period.
David Kendall, chief medical officer at Zealand Pharma, said the data "confirm the potential for clinically meaningful weight reduction with a promising and favorable tolerability profile" and highlighted the glycaemic improvements as essential to long-term benefit in this population.
The safety profile is consistent with the earlier 42-week ZUPREME-1 trial, which evaluated petrelintide in people with overweight or obesity without type 2 diabetes, lending additional confidence to the tolerability picture ahead of the Phase 3 programme.
Phase 3 and the Roche partnership
Zealand Pharma and Roche, which entered into an exclusive co-development and co-commercialisation agreement for petrelintide in 2025, have already initiated a three-trial Phase 3a programme. ZUPREME-3, ZUPREME-4, and ZUPREME-5 will together enrol approximately 7,000 participants across obesity without diabetes, obesity with type 2 diabetes, and obesity with established cardiovascular disease. First participants have begun treatment.
A separate Phase 2 trial combining petrelintide with Roche's GLP-1/GIP dual agonist enicepatide (CT-388) was planned for initiation in the second half of 2026, potentially positioning petrelintide as both a standalone agent and a combination partner in a modular obesity regimen.
The obesity pharmacotherapy market is one of the most intensely competitive in biopharma. Semaglutide and tirzepatide dominate current prescription volumes, and a growing pipeline of oral GLP-1s, amylin analogues, and novel mechanisms is advancing toward registration. Petrelintide's amylin receptor mechanism is differentiated from the GLP-1 class: amylin receptor activation is understood to reduce appetite partly by restoring sensitivity to the satiety hormone leptin, a pathway that may offer complementary or additive effects when combined with GLP-1-based agents.
Full ZUPREME-2 data are expected to be presented at an upcoming scientific conference. Investors will be watching for subgroup analyses, dose-response curves, and longer-term cardiovascular and renal biomarker data as the Phase 3 readout timeline becomes clearer.